Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;34(3):243-247.
doi: 10.2337/ds20-0078. Epub 2021 Aug 18.

Cardioprotective Effects of Pioglitazone in Type 2 Diabetes

Devjit Tripathy  1   2 , Carolina Solis-Herrera  1 , Robert E J Ryder  3
Affiliations

Cardioprotective Effects of Pioglitazone in Type 2 Diabetes

Devjit Tripathy et al. Diabetes Spectr. 2021 Aug.

Abstract

Antidiabetic medications that improve glycemic control as well as cardiovascular outcomes will be the mainstay of treatment for type 2 diabetes moving forward. This article reviews the beneficial effects of the thiazolidinedione pioglitazone of ameliorating hyperglycemia and improving cardiovascular risk factors. While the newer sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist drug classes have confirmed cardiovascular benefits, pioglitazone also has been shown to reduce major adverse cardiovascular events, in both people with type 2 diabetes and nondiabetic subjects with insulin resistance. Adverse effects associated with pioglitazone can be mitigated by its use at a lower dose and in combination with antidiabetic agents from other drug classes.

PubMed Disclaimer

References

    1. Tancredi M, Rosengren A, Svensson AM, et al. . Excess mortality among persons with type 2 diabetes. N Engl J Med 2015;373:1720–1732 - PubMed
    1. Emerging Risk Factors Collaboration; Sarwar N, Gao P, Seshasai SR, et al. . Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215–2222 - PMC - PubMed
    1. UK Prospective Diabetes Study Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853 - PubMed
    1. Zoungas S, Arima H, Gerstein HC, et al. .; Collaborators on Trials of Lowering Glucose (CONTROL) group . Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 2017;5:431–437 - PubMed
    1. Control Group; Turnbull FM, Abraira C, Anderson RJ, et al. . Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288–2298 - PubMed